Low-Intensity Ultrasound Clears Kidney Stones in 70% of Patients Without Anesthesia
The Break Wave device shatters kidney stones into passable fragments in 7 of 10 patients, no anesthesia needed, in a clinic setting.
Summary
A new in-office ultrasound device called Break Wave Lithotripsy successfully broke kidney stones into small, passable fragments in 70% of trial participants — without anesthesia, sedation, or surgery. The SOUND trial enrolled 64 adults with stones between 4–10 mm and found Break Wave matched the effectiveness of standard shock wave lithotripsy while being far gentler. Patients reported a mean pain score of just 2 out of 10, and the entire procedure took under 30 minutes with a 14-minute discharge window. The device works by delivering low-pressure standing stress waves that pulverize stones from the outside in — more like repeated light taps than a single hard blow. The FDA cleared the device in January 2026, signaling a meaningful shift toward accessible, low-burden kidney stone treatment.
Detailed Summary
Kidney stones affect roughly 1 in 11 Americans, and managing them has long required either waiting for painful natural passage or undergoing invasive or anesthesia-dependent procedures. A new clinical trial presented at the American Urological Association annual meeting suggests a far more patient-friendly option may now be available.
The SOUND trial evaluated the Break Wave Lithotripsy device across 64 adults with upper urinary tract stones ranging from 4 to 10 mm. The primary goal was to demonstrate non-inferiority to standard extracorporeal shock wave lithotripsy (ESWL). Break Wave met that bar convincingly: 70% of patients were either stone-free or had fragments reduced to 4 mm or smaller — small enough to pass naturally — with a statistically significant result (P=0.0016).
What sets Break Wave apart is its mechanism. Rather than delivering a single high-pressure shock (up to 45 megapascals in traditional ESWL), it applies repeated low-pressure ultrasonic waves at up to 8 megapascals, creating resonant stress that crumbles stones from the periphery inward — into dust rather than large fragments. This dramatically reduces tissue trauma, eliminating the need for anesthesia or sedation. Mean pain scores were just 2 out of 10.
The clinical implications are significant. 94% of procedures were completed in outpatient clinic settings, with an average treatment time of under 30 minutes and a discharge window of just 14 minutes. No patients experienced serious complications such as hematoma, urinary sepsis, or cardiac arrhythmia.
Important caveats exist. About 41% of potential participants were excluded due to poor acoustic windows that limited device delivery. The trial was relatively small at 64 participants, and longer-term stone recurrence data were not reported. The device received FDA clearance in January 2026, so real-world outcomes data remains limited. Nonetheless, for the growing population managing kidney stones, this represents a meaningful step toward accessible, low-burden care.
Key Findings
- Break Wave cleared stones in 70% of patients with no anesthesia or sedation required during treatment
- Procedure averaged under 30 minutes with a 14-minute discharge time, fully performed in clinic settings
- Mean patient pain score was only 2 out of 10, far lower than traditional shock wave lithotripsy
- Device received FDA clearance in January 2026; a next-generation version was also cleared by May 2026
- 41% of screened patients were excluded due to acoustic window limitations reducing stone targeting
Methodology
This is a meeting coverage news report from MedPage Today summarizing results presented at the 2026 AUA Annual Meeting. The evidence basis is a prospective clinical trial (SOUND) with 64 adult participants using a pre-specified non-inferiority design against an established comparator. Full peer-reviewed publication has not yet been confirmed.
Study Limitations
The trial enrolled only 64 participants, limiting statistical power and generalizability across stone types and anatomical locations. Long-term outcomes including stone recurrence rates were not reported in this meeting presentation. Full peer-reviewed publication is needed to assess methodology rigor, blinding, and follow-up protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.